Published in Hepatitis Weekly, April 23rd, 2001
Investigators reporting in the Scandinavian Journal of Infectious Diseases studied viral response to interferon (IFN)/ribavirin combination therapy in 20 patients initially given IFN monotherapy but who either did not respond to therapy (n=10) or relapsed after an initial response (n=10). Study participants received 12 weeks of therapy, starting with IFN,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.